Outcome of Baard Meeting
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Vaxfab Enterprises' board approved unaudited standalone and consolidated financial results for Q3 FY26 on 14 February 2026. On a standalone basis, the company reported a loss of ₹323.52 lakhs in Q3 FY26, slightly better than the ₹354.82 lakh loss in Q3 FY25, while revenue from operations fell to ₹1,566.29 lakhs from ₹1,906.37 lakhs YoY. On a consolidated basis, the company swung to a small profit of ₹22.98 lakhs from a ₹356.99 lakh loss a year ago, with revenue rising sharply to ₹1,566.29 lakhs from ₹914.39 lakhs. However, the 9-month standalone loss has widened sharply to ₹677.40 lakhs versus ₹354.82 lakhs in the prior year period, signalling deteriorating full-year performance.
Shareholders should view this filing with significant caution. Despite a small consolidated profit in Q3, the standalone nine-month loss has nearly doubled YoY and the auditor has flagged serious concerns, including missing records from the previous management, lack of loan documentation, no gratuity provisioning, and no expected credit loss assessment on receivables, which together amount to a qualified opinion on the financials and cast doubt on the reliability of reported numbers.